High-cost generic drugs--implications for patients and policymakers.
about
Generic versus brand-name drugs used in cardiovascular diseasesLong-Term Health Expenditure Changes in Selected Balkan CountriesThe introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.Regional variation in antibiotic prescribing among medicare part D enrollees, 2013Regulatory Solutions to the Problem of High Generic Drug Costs.Evaluating availability and price of essential medicines in Boston area (Massachusetts, USA) using WHO/HAI methodology.Three Cases of Neurologic Syndrome Caused by Donor-Derived Microsporidiosis.Merger mania: mergers and acquisitions in the generic drug sector from 1995 to 2016.Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.Medicare Part D Payments for Topical Steroids: Rising Costs and Potential Savings.Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why.Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin.Trends in pricing and generic competition within the oral antibiotic drug market in the United States.Absence of Loa loa Microfilaremia among Newly Arrived Congolese Refugees in Texas.Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending.Expediting Formulary Standardization in a Multihospital Health System Using Layered Learners.The Healthcare Delivery System
P2860
Q26775920-44A08994-5127-4DFB-B293-286793ECCEFEQ35669740-AC073F07-C2B7-4470-9EBD-8F4A26E7086FQ36087210-9C530A8C-D8A8-482B-B0AC-098D939B177DQ36219079-44C16137-91B2-4F1E-9456-92F1CEF697F8Q36387637-045B8222-3B6A-4EE5-B2F2-573675319D75Q36769374-13CF9B12-F7AA-4748-821A-73158DC3BF02Q37739666-402F61BC-F70C-47C4-97CB-CDB002828AD5Q38613640-19FC1403-69AD-4A5C-AD90-75732DD5B7D3Q38641699-4FCD3413-CD20-490A-BBA6-D580820DD249Q38814581-0D33BBF6-536C-4B95-8BE4-3E22C0E5BE4DQ38848793-CA9B6AE1-1699-4F2E-A726-76D9BD5965C0Q40162673-3F583394-4C02-47A3-8C64-78382BA57E0CQ41987286-BAC21D93-29C8-4DBE-9D52-B8C56F737D69Q41989148-B62D154D-DC0F-4DE3-935D-ACA685C34EA3Q47998668-F21858B9-A65C-49F3-A778-9577C6187E04Q52371328-FAA0E6AC-0E11-4A33-8EFD-E786975B607BQ57896423-F66C064E-57D5-46FA-94B6-545F36070FD6
P2860
High-cost generic drugs--implications for patients and policymakers.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
High-cost generic drugs--implications for patients and policymakers.
@en
High-cost generic drugs--implications for patients and policymakers.
@nl
type
label
High-cost generic drugs--implications for patients and policymakers.
@en
High-cost generic drugs--implications for patients and policymakers.
@nl
prefLabel
High-cost generic drugs--implications for patients and policymakers.
@en
High-cost generic drugs--implications for patients and policymakers.
@nl
P356
P1476
High-cost generic drugs--implications for patients and policymakers.
@en
P2093
Jonathan D Alpern
William M Stauffer
P304
P356
10.1056/NEJMP1408376
P407
P577
2014-11-01T00:00:00Z